Drug Profile
GT 02037
Alternative Names: G SRIF 14; Glycosylated somatostatin 14 analog - Glytech/Nippon Shokubai; glycosylated-SRIF; GSRIF; GT-02037Latest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Glytech; Nippon Shokubai
- Developer Pharmaspur Inc
- Class Antisecretories; Peptide hormones; Pituitary hormone release inhibiting hormones
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acromegaly
Most Recent Events
- 20 Jul 2023 Phase-II clinical trials in Acromegaly (In volunteers) in Japan (SC) (GlyTech pipeline, July 2023)
- 28 Dec 2020 No recent reports of development identified for clinical-Phase-Unknown development in Acromegaly(In volunteers) in Japan (SC, Injection)
- 18 Dec 2020 Phase I development in Acromegaly (In volunteers) is still on going in Japan (SC) (JapicCTI205248)